Johnson & Johnson and GlaxoSmithKline have contributed to a series B round for Pulmocide, a respiratory therapy spinout of Imperial College London.

Touchstone Innovations, which previously led a series A in 2013, has put $3.7m into the series B round and participated alongside several corporates such as GlaxoSmithKline.

The WuXi PharmaTech-backed infusion pump developer has raised the first $10m of a three-tranche round expected to close at $50m.

Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.

The Qualcomm-backed mobile electrocardiogram developer has raised new funding in a round co-led by strategic investors Omron Healthcare and Mayo Clinic.

Suzhou Ribo Life Science, which is developing RNA therapies for hepatitis B, hyperlipidaemia and liver cancer, has secured funding in a Legend Capital-backed series B round.

Heritage Provider Network is among a consortium of investors that provided $38m in series A capital to genome editing technology developer eGenesis.

Nottingham spinout Monica Healthcare, which has developed monitoring technology for expectant mothers and their babies, has been acquired by GE Healthcare.

Oxford University has partnered Kingsley Capital Partners to conduct research into cannabis-based medication through a new company dubbed Oxford Cannabinoid Technologies.